April 21, 2017 / 5:54 PM / 5 months ago

BRIEF-EU Medicines Agency recommendations for April 2017

April 21 (Reuters) - EU Medicines Agency -

* EU Medicines Agency recommendations for April 2017

* EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz’s Rixathon Non-Hodgkin’s Lymphoma (NHL), chronic lymphocytic leukaemia

* Recommends approval of Sanofi SA and Regeneron’s Kevzara (Sarilumab) for treatment of rheumatoid arthritis

* Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug

* Recommends approval of Pfizer’s Besponsa for treatment of acute lymphoblastic leukaemia

* Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug

* Recommends approval of GMP-Orphan SA’s Cuprior for treatment of Wilson’s disease

* Recommends approval of Almirall’s Skilarence for treatment of psoriasis

* Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia Source text - bit.ly/2oulvdj (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below